Stryker Co. (NYSE:SYK) Shares Sold by Northcape Wealth Management LLC

Northcape Wealth Management LLC trimmed its holdings in Stryker Co. (NYSE:SYK) by 0.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,252 shares of the medical technology company’s stock after selling 73 shares during the period. Northcape Wealth Management LLC’s holdings in Stryker were worth $2,771,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. HBC Financial Services PLLC acquired a new position in Stryker in the fourth quarter valued at about $37,000. Bourgeon Capital Management LLC purchased a new position in Stryker during the fourth quarter worth about $37,000. Venturi Wealth Management LLC increased its position in shares of Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after acquiring an additional 67 shares during the last quarter. Finally, Armstrong Advisory Group Inc. increased its holdings in Stryker by 40.0% in the 4th quarter. Armstrong Advisory Group Inc. now owns 140 shares of the medical technology company’s stock valued at $42,000 after purchasing an additional 40 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the subject of a number of research analyst reports. Truist Financial raised their target price on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Citigroup boosted their price objective on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. TD Cowen increased their target price on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Finally, Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

Insider Buying and Selling

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 212,109 shares of company stock valued at $72,845,768. Corporate insiders own 5.50% of the company’s stock.

Stryker Price Performance

Shares of SYK traded down $2.55 during mid-day trading on Tuesday, hitting $336.32. The company’s stock had a trading volume of 2,480,477 shares, compared to its average volume of 1,301,242. The firm has a market capitalization of $127.96 billion, a P/E ratio of 41.09, a P/E/G ratio of 2.70 and a beta of 0.89. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The firm has a 50-day simple moving average of $348.68 and a 200 day simple moving average of $316.14. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. During the same quarter last year, the business earned $2.14 earnings per share. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. Analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.